fujirebio - MRCHF

MRCHF

Close Chg Chg %
21.18 -1.13 -5.31%

Open Market

20.05

-1.13 (5.31%)

Volume: 650.00

Last Updated:

Jun 16, 2026, 3:34 PM EDT

Company Overview: fujirebio - MRCHF

MRCHF Key Data

Open

$19.22

Day Range

19.22 - 20.05

52 Week Range

18.60 - 28.06

Market Cap

$1.08B

Shares Outstanding

55.49M

Public Float

51.35M

Beta

0.22

Rev. Per Employee

N/A

P/E Ratio

24.25

EPS

$0.79

Yield

420.50%

Dividend

$0.39

EX-DIVIDEND DATE

Mar 31, 2027

SHORT INTEREST

N/A

AVERAGE VOLUME

176.42

 

MRCHF Performance

1 Week
 
0.00%
 
1 Month
 
5.25%
 
3 Months
 
-4.48%
 
1 Year
 
33.31%
 
5 Years
 
N/A
 

MRCHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About fujirebio - MRCHF

H.U. Group Holdings, Inc. provides the strategic planning, investor relations, public relations, and supervisory management of the entire group. It operates through the following segments: Inspection and Related Services Business, Clinical Diagnostic Reagent Business, and Healthcare Related Services Business segments. The Inspection and Related Services Business segment provides comprehensive Inspection services to medical institutions. The Clinical Diagnostics Reagent Business segment manufactures and sells clinical diagnostics. The Healthcare Related Services Business segment operates a sterilization-related business and a home and welfare equipment business. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

MRCHF At a Glance

H.U. Group Holdings, Inc.
Akasaka Intercity AIR
Tokyo, Tokyo 107-0052
Phone 81-3-6279-0801 Revenue 1.64B
Industry Medical/Nursing Services Net Income 45.28M
Sector Health Services 2026 Sales Growth 2.972%
Fiscal Year-end 03 / 2027 Employees 5,157
View SEC Filings

MRCHF Valuation

P/E Current 24.247
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.876
Price to Sales Ratio 0.687
Price to Book Ratio 1.289
Price to Cash Flow Ratio 7.88
Enterprise Value to EBITDA 7.339
Enterprise Value to Sales 0.787
Total Debt to Enterprise Value 0.362

MRCHF Efficiency

Revenue/Employee 318,306.429
Income Per Employee 8,779.864
Receivables Turnover 5.65
Total Asset Turnover 0.925

MRCHF Liquidity

Current Ratio 1.721
Quick Ratio 1.395
Cash Ratio 0.654

MRCHF Profitability

Gross Margin 28.609
Operating Margin 1.932
Pretax Margin 3.469
Net Margin 2.758
Return on Assets 2.55
Return on Equity 5.086
Return on Total Capital 3.402
Return on Invested Capital 3.646

MRCHF Capital Structure

Total Debt to Total Equity 54.093
Total Debt to Total Capital 35.104
Total Debt to Total Assets 27.79
Long-Term Debt to Equity 33.328
Long-Term Debt to Total Capital 21.629
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fujirebio - MRCHF

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
1.93B 1.64B 1.59B 1.64B
Sales Growth
-20.71% -14.81% -2.84% +2.97%
Cost of Goods Sold (COGS) incl D&A
1.30B 1.24B 1.19B 1.17B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
145.38M 144.52M 136.08M 144.38M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
-10.77% -4.45% -4.21% -1.68%
Gross Income
623.85M 396.53M 402.20M 469.61M
Gross Income Growth
-35.66% -36.44% +1.43% +16.76%
Gross Profit Margin
+32.39% +24.17% +25.23% +28.61%
2023 2024 2025 2026 5-year trend
SG&A Expense
451.25M 424.53M 386.81M 437.89M
Research & Development
70.54M 77.98M 71.46M 74.13M
Other SG&A
380.71M 346.55M 315.36M 363.76M
SGA Growth
-13.27% -5.92% -8.88% +13.20%
Other Operating Expense
- - - -
-
Unusual Expense
12.05M 1.89M 2.36M 484.43K
EBIT after Unusual Expense
160.55M (29.89M) 13.03M 31.24M
Non Operating Income/Expense
11.29M (20.12M) 11.93M 30.28M
Non-Operating Interest Income
1.79M 3.14M 3.33M 2.67M
Equity in Earnings of Affiliates
(14.42M) (23.81M) (4.82M) (6.00M)
Interest Expense
2.72M 2.76M 3.88M 4.55M
Interest Expense Growth
-22.51% +1.43% +40.31% +17.43%
Gross Interest Expense
2.72M 2.76M 3.88M 4.55M
Interest Capitalized
- - - -
-
Pretax Income
169.10M (52.76M) 21.09M 56.95M
Pretax Income Growth
-54.02% -131.20% +139.97% +170.05%
Pretax Margin
+8.78% -3.22% +1.32% +3.47%
Income Tax
53.37M (457.02K) 3.17M 12.46M
Income Tax - Current - Domestic
43.33M 26.48M 24.42M 8.22M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
10.05M (26.94M) (21.25M) 4.23M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(14.42M) (23.81M) (4.82M) (6.00M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
115.72M (52.30M) 17.91M 44.49M
Minority Interest Expense
- - (190.23K) (789.69K)
-
Net Income
115.72M (52.30M) 18.10M 45.28M
Net Income Growth
-56.07% -145.20% +134.62% +150.09%
Net Margin Growth
+6.01% -3.19% +1.14% +2.76%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
115.72M (52.30M) 18.10M 45.28M
Preferred Dividends
- - - -
-
Net Income Available to Common
115.72M (52.30M) 18.11M 45.28M
EPS (Basic)
2.0338 -0.9194 0.3188 0.8063
EPS (Basic) Growth
-56.01% -145.21% +134.67% +152.92%
Basic Shares Outstanding
56.90M 56.89M 56.82M 56.15M
EPS (Diluted)
2.0337 -0.9194 0.3188 0.8057
EPS (Diluted) Growth
-56.01% -145.21% +134.67% +152.73%
Diluted Shares Outstanding
56.90M 56.89M 56.82M 56.20M
EBITDA
317.98M 116.51M 151.47M 176.10M
EBITDA Growth
-43.91% -63.36% +30.00% +16.26%
EBITDA Margin
+16.51% +7.10% +9.50% +10.73%

Fujirebio in the News